Sordo-Bahamonde, C.; Lorenzo-Herrero, S.; González-Rodríguez, A.P.; Payer, Á.R.; González-García, E.; López-Soto, A.; Gonzalez, S.
LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. Cancers 2021, 13, 2112.
https://doi.org/10.3390/cancers13092112
AMA Style
Sordo-Bahamonde C, Lorenzo-Herrero S, González-Rodríguez AP, Payer ÁR, González-García E, López-Soto A, Gonzalez S.
LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. Cancers. 2021; 13(9):2112.
https://doi.org/10.3390/cancers13092112
Chicago/Turabian Style
Sordo-Bahamonde, Christian, Seila Lorenzo-Herrero, Ana P. González-Rodríguez, Ángel R. Payer, Esther González-García, Alejandro López-Soto, and Segundo Gonzalez.
2021. "LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia" Cancers 13, no. 9: 2112.
https://doi.org/10.3390/cancers13092112
APA Style
Sordo-Bahamonde, C., Lorenzo-Herrero, S., González-Rodríguez, A. P., Payer, Á. R., González-García, E., López-Soto, A., & Gonzalez, S.
(2021). LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. Cancers, 13(9), 2112.
https://doi.org/10.3390/cancers13092112